Sangamo Therapeutics Inc SGMO:NASDAQ

Last Price$5.85NASDAQ Closing Price as of 4:00PM ET 8/10/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.61(11.64%)
Bid (Size)$5.84 (12)
Ask (Size)$5.99 (1)
Day Low / High$5.28 - 5.87
Volume2.5 M

View Biotechnology IndustryPeer Comparison as of 08/10/2022


Sangamo Therapeutics Inc ( NASDAQ )

Price: $5.85
Change: +0.61 (11.64%)
Volume: 2.5 M
4:00PM ET 8/10/2022

Anavex Life Sciences Corp ( NASDAQ )

Price: $11.66
Change: +0.86 (7.96%)
Volume: 742.0 K
3:59PM ET 8/10/2022

Geron Corp ( NASDAQ )

Price: $2.16
Change: +0.09 (4.35%)
Volume: 4.2 M
4:00PM ET 8/10/2022

Coherus BioSciences Inc ( NASDAQ )

Price: $12.97
Change: +1.91 (17.27%)
Volume: 2.0 M
4:00PM ET 8/10/2022

Stoke Therapeutics Inc ( NASDAQ )

Price: $22.49
Change: +0.38 (1.72%)
Volume: 319.1 K
4:00PM ET 8/10/2022

Read more news Recent News

--Truist Trims Price Target for Sangamo Therapeutics to $17 From $19, Maintains Buy Rating
12:47PM ET 8/08/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Posts Q2 Revenue $29.4M
4:03PM ET 8/04/2022 MT Newswires


-- Earnings Flash (SGMO) SANGAMO THERAPEUTICS Posts Q2 Revenue $29.4M
4:03PM ET 8/04/2022 MT Newswires


Sangamo Therapeutics Gets Orphan Medicinal Product Designation for Investigational Cell Therapy in Europe
11:06AM ET 7/21/2022 MT Newswires

Sangamo Therapeutics (SGMO) said Thursday that the European Commission has granted an orphan medicinal product designation to its chimeric antigen receptor...

Company Profile

Business DescriptionSangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA. View company web site for more details
Address7000 Marina Boulevard
Brisbane, California 94005
Number of Employees302
Recent SEC Filing08/09/20228-K
President, Chief Executive Officer & DirectorAlexander D. Macrae
Chief Operating Officer & Executive Vice PresidentMark D. McClung
Senior VP, Chief Financial & Accounting OfficerPrathyusha Durabaibu
Executive Vice President-Technical OperationsR. Andrew Ramelmeier

Company Highlights

Price Open$5.40
Previous Close$5.24
52 Week Range$3.12 - 11.49
Market Capitalization$915.8 M
Shares Outstanding156.6 M
SectorHealth Technology
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.18
Beta vs. S&P 500N/A
Revenue$84.5 M
Net Profit Margin-150.96%
Return on Equity-48.07%

Analyst Ratings as of 02/28/2022

Consensus RecommendationConsensus Icon
Powered by Factset